Measuring health-related quality of life in clinical trials in cystic fibrosis

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Measuring health-related quality of life in clinical trials in cystic fibrosis. / Abbott, Janice ; Hart, Anna; Havermans, T et al.
In: Journal of Cystic Fibrosis, Vol. 10, No. Supplement 2, 06.2011, p. S82-S85.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Abbott, J, Hart, A, Havermans, T, Matossian, A, Goldbeck, L, Barreto, C, Bergsten-Brucefors, A, Besier, T, Catastini, P, Lupi, F & Staab, D 2011, 'Measuring health-related quality of life in clinical trials in cystic fibrosis', Journal of Cystic Fibrosis, vol. 10, no. Supplement 2, pp. S82-S85. https://doi.org/10.1016/S1569-1993(11)60013-1

APA

Abbott, J., Hart, A., Havermans, T., Matossian, A., Goldbeck, L., Barreto, C., Bergsten-Brucefors, A., Besier, T., Catastini, P., Lupi, F., & Staab, D. (2011). Measuring health-related quality of life in clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 10(Supplement 2), S82-S85. https://doi.org/10.1016/S1569-1993(11)60013-1

Vancouver

Abbott J, Hart A, Havermans T, Matossian A, Goldbeck L, Barreto C et al. Measuring health-related quality of life in clinical trials in cystic fibrosis. Journal of Cystic Fibrosis. 2011 Jun;10(Supplement 2):S82-S85. doi: 10.1016/S1569-1993(11)60013-1

Author

Abbott, Janice ; Hart, Anna ; Havermans, T et al. / Measuring health-related quality of life in clinical trials in cystic fibrosis. In: Journal of Cystic Fibrosis. 2011 ; Vol. 10, No. Supplement 2. pp. S82-S85.

Bibtex

@article{4147c0fc91ca46d5822dfcc30c69c31d,

title = "Measuring health-related quality of life in clinical trials in cystic fibrosis",

abstract = "The inclusion of health-related quality of life (HRQoL) as an outcome measure in cystic fibrosis (CF) clinical trials can supply important patient-reported information not captured by other endpoints. Both an appropriate HRQoL measure and sound methodology are required in order to draw valid inferences about treatments and HRQoL. This paper provides the current consensus of the HRQoL Outcomes Group. Particular consideration has been given to the appropriateness of measurement scales, the rationale for including specific domains as endpoints, the importance of considering baseline ceiling effects and the difficulties of data interpretation. Guidance is provided on HRQoL measurement in National and European CF clinical trials.",

keywords = "Cystic fibrosis, Clinical trial , Quality of life measurement , Patient-reported outcome",

author = "Janice Abbott and Anna Hart and T Havermans and A Matossian and L Goldbeck and C Barreto and A Bergsten-Brucefors and T Besier and P Catastini and F Lupi and D Staab",

year = "2011",

month = jun,

doi = "10.1016/S1569-1993(11)60013-1",

language = "English",

volume = "10",

pages = "S82--S85",

journal = "Journal of Cystic Fibrosis",

publisher = "Elsevier",

number = "Supplement 2",

}

RIS

TY - JOUR

T1 - Measuring health-related quality of life in clinical trials in cystic fibrosis

AU - Abbott, Janice

AU - Hart, Anna

AU - Havermans, T

AU - Matossian, A

AU - Goldbeck, L

AU - Barreto, C

AU - Bergsten-Brucefors, A

AU - Besier, T

AU - Catastini, P

AU - Lupi, F

AU - Staab, D

PY - 2011/6

Y1 - 2011/6

N2 - The inclusion of health-related quality of life (HRQoL) as an outcome measure in cystic fibrosis (CF) clinical trials can supply important patient-reported information not captured by other endpoints. Both an appropriate HRQoL measure and sound methodology are required in order to draw valid inferences about treatments and HRQoL. This paper provides the current consensus of the HRQoL Outcomes Group. Particular consideration has been given to the appropriateness of measurement scales, the rationale for including specific domains as endpoints, the importance of considering baseline ceiling effects and the difficulties of data interpretation. Guidance is provided on HRQoL measurement in National and European CF clinical trials.

AB - The inclusion of health-related quality of life (HRQoL) as an outcome measure in cystic fibrosis (CF) clinical trials can supply important patient-reported information not captured by other endpoints. Both an appropriate HRQoL measure and sound methodology are required in order to draw valid inferences about treatments and HRQoL. This paper provides the current consensus of the HRQoL Outcomes Group. Particular consideration has been given to the appropriateness of measurement scales, the rationale for including specific domains as endpoints, the importance of considering baseline ceiling effects and the difficulties of data interpretation. Guidance is provided on HRQoL measurement in National and European CF clinical trials.

KW - Cystic fibrosis

KW - Clinical trial

KW - Quality of life measurement

KW - Patient-reported outcome

U2 - 10.1016/S1569-1993(11)60013-1

DO - 10.1016/S1569-1993(11)60013-1

M3 - Journal article

VL - 10

SP - S82-S85

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - Supplement 2

ER -

Research

Links

Text available via DOI:

Keywords